Anna Diaz Triola
Corporate Officer/Principal presso ENTASIS THERAPEUTICS HOLDINGS INC.
Profilo
Anna Diaz Triola is currently the Chief Commercial Officer at Entasis Therapeutics Holdings, Inc. She previously held the position of Vice President-Marketing at Summit Therapeutics Ltd.
and Flexion Therapeutics, Inc. Diaz Triola received her undergraduate degree from Wellesley College and her MBA from Harvard Business School.
Posizioni attive di Anna Diaz Triola
Società | Posizione | Inizio |
---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 19/07/2021 |
Precedenti posizioni note di Anna Diaz Triola
Società | Posizione | Fine |
---|---|---|
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Vendite & Marketing | - |
FLEXION THERAPEUTICS, INC. | Vendite & Marketing | - |
Formazione di Anna Diaz Triola
Wellesley College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Anna Diaz Triola